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Darko Zdravkovic1,2 and Svetlana Jelic1,2Abstract
The incidence of breast carcinoma following prophylactic mastectomy is probably less than 2%. We present a
43-year-old female to male transsexual who developed breast cancer 1 year after bilateral nipple- sparing
subcutaneous mastectomy as part of female to male gender reassignment surgery. In addition to gender
reassignment surgery, total abdominal hysterectomy with bilateral salpingo-oophorectomy (to avoid the patient
from entering menopause and to eliminate any subsequent risk of iatrogenic endometrial carcinoma), colpocleisys,
metoidioplasty, phalloplasty, urethroplasty together with scrotoplasty/placement of testicular prosthesis and
perineoplasty were also performed. Before the sex change surgery, the following diagnostic procedures were
performed: breast ultrasound and mammography (which were normal), lung radiography (also normal) together
with abdominal ultrasound examination, biochemical analysis of the blood and hormonal status.
According to medical literature, in the last 50 years only three papers have been published with four cases of breast
cancer in transsexual female to male patients. All hormonal pathways included in this complex hormonal and
surgical procedure of transgender surgery have important implications for women undergoing prophylactic
mastectomy because of a high risk of possible breast cancer.
Keywords: Female to male surgery, Mastectomy, Breast cancerBackground
The incidence of breast carcinoma after prophylactic mas-
tectomy is probably less than 2% [1]. Several studies such
as those by Pennisi and Capozzi [2] and by Woods [3] have
been conducted, where only few patients, from more than
1,000 patients included in the study (prophylactic subcuta-
neous mastectomy), developed breast cancer after years of
follow-up (incidence rate 0.6%). However, one of the major
concerns about nipple sparing mastectomy is the persistent
risk of breast cancer development when this is used for
prophylaxis, with much controversy about the safety of
these procedures from an oncological point of view [4,5].
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reproduction in any medium, provided the orof long-term testosterone use on breast cancer risk. In a
20-year follow-up study of 110 female to male transsexuals
in Serbia, there were none with breast carcinoma [6].Case presentation
A female to male transsexual, who underwent complex sex
reassignment surgery after bilateral subcutaneous nipple
sparing mastectomy (weight of removed breast tissue: left
breast tissue, 275 g; right breast tissue, 295 g), presented 1
year after surgery with a painless left areoral mass. Samples
of the left and right breast tissues sent for pathological
analysis following subcutaneous mastectomy were benign.
The patient was 42 years old at the time the breast cancer
was discovered, and 41 years old at the time of transgender
surgery. The patient started testosterone therapy 18 months
prior to sex reassignment (250 mg intramuscularly every 2
weeks). After the sex reassignment surgery, he received
250mg testosterone every 17 days for the next 12Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was premenopausal.
The patient did not have any relatives with a history
of any type of cancer. Family history of breast cancer
and ovarian cancer in first-degree or second-degree
relatives was thus negative, with no prior breast biopsies
in clinical history, and therefore he was not a high-risk
patient for breast cancer. BRCA1 and BRCA2 testing
were not performed.
A routine chest X-ray image revealed an areolar mass on
the left-hand side with N2 axillary node status, as well as
lung metastases. Metastases in both lungs were confirmed
by multislice spiral computed tomography. The classi-
fication, according to the American Joint Committee on
Cancer, was T2N2M1, stage IV. Liver function tests and
tumor markers (Ca 15–3) were normal.
Hormone profile studies confirmed satisfactory andro-
gen replacement (normal testosterone with luteinizing
hormone and follicle-stimulating hormone suppression.
A neoadjuvant therapy (fluorouracil, adriamycin and
cyclophosphamide) 3-week protocol was administered to
the patient, for six cycles. Owing to shrinkage of the tumor
mass, radical mastectomy together with axillary dissection
was performed after neoadjuvant therapy was finished.
Trastuzumab (6 mg/kg intravenous infusion over 30 to 90
minutes every 3 weeks) was administered to the patient in
combination with paclitaxel (80 mg/m2 every week) as
adjuvant chemotherapy. Both drugs were administered to
the patient after six cycles of fluorouracil, adriamycin and
cyclophosphamide and radical breast surgery.Results
Histological examination of the breast tumor showed inva-
sive ductal carcinoma of breast tissue and metastasis of in-
vasive ductal carcinoma in the lymph nodes of the left
axilla (12+/13),while the lymph nodes of the right axilla
were negative for metastasis. Estrogen and progesterone
receptors were negative although the Her 2/neu receptor
was positive (60% of the tumor cells were 3+). Receptors
for Ki-67 (50%) were positive. Androgen receptors (ARs)
in breast cancer were also positive (2%).
Assessment of the tumor response following neoadju-
vant therapy was good, with shrinkage of the primary
tumor in the left breast from 63mm×54mm×50mm to
40mm×40mm×40mm.
For evaluation, a scintigraphy was performed along
with four multislice spiral computed tomography scans
(performed quarterly). No liver or bone metastases were
revealed. Prior to neoadjuvant therapy, lung metastases
were present in both the left and right lungs, with a
maximum diameter of 11mm. Following neoadjuvant
therapy these metastases were found to be smaller, with
a maximum diameter of 9mm. After radical mastectomyand axillary dissection and 2 months after the start of
treatment with trastuzumab and paclitaxel, only one
metastasis with a diameter of 5mm was observed in the
right lung on multislice spiral computed tomography of
the thorax and abdomen. There were no metastases on
other parts of the body.Discussion
The incidence of breast carcinoma after prophylactic
mastectomy is probably less than 2% [1]. Several studies
such as those by Pennisi and Capozzi [2] and by Woods
[3] have been conducted, where only a few patients,
from more than 1,000 patients included in the study
(prophylactic subcutaneous mastectomy), developed
breast cancer after years of follow-up (incidence rate
0.6%). However, one of the major concerns about nipple
sparing mastectomy is the persistent risk of breast can-
cer development when this is used for prophylaxis, with
much controversy about the safety of these procedures
from an oncological point of view [4,5]. At present there
are no randomized studies on the effects of long-term
testosterone use on breast cancer risk. In a 20-year
follow-up study of 110 female to male transsexuals in
Serbia, there were none with breast carcinoma [6].
Our presenting case of breast cancer and lung metastases
in a female to male transsexual exposed to exogenous
androgens is very rare and has not previously been
described. Direct effects of androgens on inducing breast
cell proliferation and cancer via the AR are biologically
impossible. In our patient, androgen-positive receptors
were found in only 2% of breast tumor cells. In vitro studies
have shown an inhibitory effect of androgens on breast cell
proliferation and growth [7]. Negative findings for estrogen
and progesterone receptors open the question of whether
there is any hormonal dependence, or genetically deter-
mined carcinogenesis, irrespective of testosterone therapy.
The role of elevated androgen levels and the AR expres-
sion in male breast cancer as well as in female breast cancer
is still unclear [8,9].
Based on a few early articles by Grattarola [10], the
androgen excess theory states that urinary androgen
excretion and intratumoral estrogen receptor status
confirm the existence of hormone-dependent disease
and predict the clinical outcome from ovariectomy in
patients with metastatic breast cancer.
Positive AR immunostaining was found in approxi-
mately 70% of invasive female breast carcinomas and in
a significant number of triple-negative tumors [11].
A recent study of case records for 1,849 patients with
breast cancer revealed that positive AR immunostaining
was inversely correlated with clinical stage, histological
grade and mitotical score. Positive AR immunostaining was
therefore associated with less aggressive tumors [12].
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drugs is effective against increased estrogen production
but quite ineffective against androgen excess. Additional
therapy in these cases might be needed as well as deter-
mination of the origin (ovarian or adrenal) of the andro-
gen excess in the particular patient. Ovariectomy (surgical,
radiological or medical) would be indicated if the excess
originates from the ovaries, while sulfatase inhibitors
would be indicated in patients with adrenal source of
androgen excess [9].
The Surveillance, Epidemiology and End Results can-
cer registry,which includes more than 2,000 male
patients, has highlighted the fact that 93.7% of male
breast cancers were ductal or unclassified, while 2.6%
were papillary, 1.8% were mucinous and only 1.5%
were lobular [13]. Breast cancers in men are signifi-
cantly more likely to express hormone receptors than
cancers in the female breast [8,13]. As much as 81% of
male breast cancers express the progesterone receptor,
and even 90% of them express the estrogen receptor.
Knowing this, adjuvant hormonal therapy (including
progestins, androgens, steroids, aminoglutethamide,
estrogens, letrozole) has an important role in the treat-
ment of these patients. However, literature data report
AR expression in 34 to 95% of male breast cancer with
no clear association with its prognosis [8]. Mutations
in the AR gene have been reported in male patients
with breast cancer [14], but again no causal association
could be demonstrated.
It would be even more difficult to hypothesize on the
role of androgen excess and the AR expression in the
evolution of breast cancer in female to male transsexual
patients due to the small number of such cases reported
in literature. However, for those clinicians who deal with
these patients, it is important to bear in mind all of the
complex relationships between AR expression in breast
cancer and other steroid receptors and growth factors.
There are certain dilemmas that must be addressed. In
spite of the fact that the excised glandular tissue was
pathologically benign, were the diagnostic procedures
performed before sex reassignment surgery in our case
insufficiently precise or insufficiently reliable, so that
breast cancer had not been revealed in time, or was an-
drogen supplementation the trigger for activation of
invasive ductal carcinoma of the breast and potential
high-speed malignancy of breast cancer, resulting in me-
tastases in both lungs within a very short time?
According to medical literature, in the last 50 years there
have been only three papers with four cases of breast
cancer in transsexual female to male patients [15-17]. The
first case, a 33-year-old female to male transsexual who
developed breast cancer 10 years after cosmetic bilateral
subcutaneous mastectomy and nipple reimplantation, was
described in an article in Breast [15]. The following twopatients mentioned in Clinical Breast were breast cancers
diagnosed in two female to male transsexuals who had been
treated with a supraphysiological doses of testosterone [16].
In addition, Gooren reported a single case of breast cancer
in a female to male transsexual receiving testosterone
hormone replacement therapy [17].
One should point out that the regularly performed
bilateral removal of breast tissue including the nipple–
areola complex, axillary tail and pectoral fascia was
probably insufficient, and that breast cancer occurred
in the residual breast tissue of the transsexual patient.
However, it is very hard to speculate whether the
patient could have developed breast cancer after
oophorectomy with androgen supplementation if a
total mastectomy had been performed.
As well as demonstrating the complex and poorly
understood hormonal influences involved in the etiology
of breast cancer, our patient’s management raised some
important clinical issues. In this study the potential
causative role of androgen replacement in breast malig-
nancy, and the benefits, risks and safety of such treat-
ment in breast cancer survivors, were discussed. The
protection afforded to high-risk women undergoing
prophylactic mastectomy is reviewed and the optimal
hormonal management of this case was considered.
Conclusion
This rare and very interesting case demonstrates that, in
spite of the involvement of different types of specialists,
such as surgeons, oncosurgeons, gynecologists and endocri-
nologists, very complex procedures of sex reassignment
surgery can sometimes result in possible malignant disease
escaping medical control.
Revealing and publishing cases such as this serves to
raise awareness among doctors when starting the
requested sex change process in these surgically and endo-
crinologically very complicated patients. The case also
shows a need for change in clinical practice, to include
magnetic resonance imaging prior to prophylactic mastec-
tomy as a significantly more sensitive method for revealing
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